Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Secondary Polycythemia Medication

  • Author: Srikanth Nagalla, MBBS, MS, FACP; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
 
Updated: Apr 14, 2016
 
 

Medication Summary

No medications are available to treat the blood disorder of secondary polycythemia. Treat the underlying health problem.

 
 
Contributor Information and Disclosures
Author

Srikanth Nagalla, MBBS, MS, FACP Director, Clinical Hematology, Cardeza Foundation for Hematologic Research; Assistant Professor of Medicine, Division of Hematology, Associate Program Director, Hematology/Medical Oncology Fellowship, Assistant Program Director, Internal Medicine Residency, Jefferson Medical College of Thomas Jefferson University

Srikanth Nagalla, MBBS, MS, FACP is a member of the following medical societies: American Society of Hematology, Association of Specialty Professors

Disclosure: Nothing to disclose.

Coauthor(s)

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ronald A Sacher, MB, BCh, FRCPC, DTM&H Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, FRCPC, DTM&H is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society on Thrombosis and Haemostasis, Royal College of Physicians and Surgeons of Canada, American Clinical and Climatological Association, International Society of Blood Transfusion

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: GSK Pharmaceuticals,Alexion,Johnson & Johnson Talecris,,Grifols<br/>Received honoraria from all the above companies for speaking and teaching.

Chief Editor

Koyamangalath Krishnan, MD, FRCP, FACP Dishner Endowed Chair of Excellence in Medicine, Professor of Medicine, James H Quillen College of Medicine at East Tennessee State University

Koyamangalath Krishnan, MD, FRCP, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Society of Hematology, Royal College of Physicians

Disclosure: Nothing to disclose.

Additional Contributors

Karen Seiter, MD Professor, Department of Internal Medicine, Division of Oncology/Hematology, New York Medical College

Karen Seiter, MD is a member of the following medical societies: American Association for Cancer Research, American College of Physicians, American Society of Hematology

Disclosure: Received honoraria from Novartis for speaking and teaching; Received consulting fee from Novartis for speaking and teaching; Received honoraria from Celgene for speaking and teaching.

References
  1. Stuart BJ, Viera AJ. Polycythemia vera. Am Fam Physician. 2004 May 1. 69(9):2139-44. [Medline]. [Full Text].

  2. Passamonti F. How to manage polycythemia vera. Leukemia. 2011 Dec 9. [Medline].

  3. McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hematol. 2008 Dec. 30(6):447-59. [Medline].

  4. Esparcieux A, Francina A, Vital-Durand D. [Abnormal haemoglobins with high oxygen affinity in the differential diagnostics of polycythemia]. Rev Med Interne. 2011 Oct. 32(10):e105-7. [Medline].

  5. Balcerzak SP, Bromberg PA. Secondary polycythemia. Semin Hematol. 1975 Oct. 12(4):353-82. [Medline].

  6. Prchal JF, Prchal JT. Molecular basis for polycythemia. Curr Opin Hematol. 1999 Mar. 6(2):100-9. [Medline].

  7. Patnaik MM, Tefferi A. The complete evaluation of erythrocytosis: congenital and acquired. Leukemia. 2009 May. 23(5):834-44. [Medline].

  8. McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hematol. 2008 Dec. 30(6):447-59. [Medline].

  9. Zhan H, Spivak JL. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Clin Adv Hematol Oncol. 2009 May. 7(5):334-42. [Medline].

  10. Carillo S, Henry L, Lippert E, Girodon F, Guiraud I, Richard C, et al. Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia. J Mol Diagn. 2011 May. 13(3):263-70. [Medline]. [Full Text].

  11. Squizzato A, Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev. 2008 Apr 16. CD006503. [Medline].

  12. Lee FS. Genetic causes of erythrocytosis and the oxygen-sensing pathway. Blood Rev. 2008 Nov. 22(6):321-32. [Medline].

  13. Gonzales GF, Gasco M, Tapia V, Gonzales-Castañeda C. High serum testosterone levels are associated with excessive erythrocytosis of chronic mountain sickness in men. Am J Physiol Endocrinol Metab. 2009 Jun. 296(6):E1319-25. [Medline]. [Full Text].

  14. Patakas DA, Christaki PI, Louridas GE, Sproule BJ. Control of breathing in patients with chronic obstructive lung diseases and secondary polycythemia after venesection. Respiration. 1986. 49(4):257-62. [Medline].

  15. Calverley PM, Leggett RJ, McElderry L, Flenley DC. Cigarette smoking and secondary polycythemia in hypoxic cor pulmonale. Am Rev Respir Dis. 1982 May. 125(5):507-10. [Medline].

  16. Schwarcz TH, Hogan LA, Endean ED, et al. Thromboembolic complications of polycythemia: polycythemia vera versus smokers' polycythemia. J Vasc Surg. 1993 Mar. 17(3):518-22; discussion 522-3. [Medline].

  17. Percy MJ, Beard ME, Carter C, Thein SL. Erythrocytosis and the Chuvash von Hippel-Lindau mutation. Br J Haematol. 2003 Oct. 123(2):371-2. [Medline].

  18. Van Maerken T, Hunninck K, Callewaert L, et al. Familial and congenital polycythemias: a diagnostic approach. J Pediatr Hematol Oncol. 2004 Jul. 26(7):407-16. [Medline].

  19. Kralovics R, Indrak K, Stopka T, et al. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood. 1997 Sep 1. 90(5):2057-61. [Medline]. [Full Text].

  20. Ip F, di Pierro I, Brown R, et al. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol. 2009 Nov 10. [Medline].

  21. Remacha AF, Montserrat I, Santamaria A, et al. Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study. Haematologica. 1997 Jul-Aug. 82(4):406-10. [Medline]. [Full Text].

  22. Sondel PM, Tripp ME, Ganick DJ, Levy JM, Shahidi NT. Phlebotomy with iron therapy to correct the microcytic polycythemia of chronic hypoxia. Pediatrics. 1981 May. 67(5):667-70. [Medline].

  23. Kershenovich S, Modiano M, Ewy GA. Markedly decreased coronary blood flow in secondary polycythemia. Am Heart J. 1992 Feb. 123(2):521-3. [Medline].

  24. Lubarsky DA, Gallagher CJ, Berend JL. Secondary polycythemia does not increase the risk of perioperative hemorrhagic or thrombotic complications. J Clin Anesth. 1991 Mar-Apr. 3(2):99-103. [Medline].

  25. Menon D, York EL, Bornstein RA, Jones RL, Sproule BJ. Optimal hematocrit and blood viscosity in secondary polycythemia as determined from cerebral blood flow. Clin Invest Med. 1981. 4(2):117-21. [Medline].

  26. Rapado I, Albizua E, Ayala R, Hernández JA, Garcia-Alonso L, Grande S, et al. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann Hematol. 2008 Sep. 87(9):741-9. [Medline].

  27. York EL, Jones RL, Menon D, Sproule BJ. Effects of secondary polycythemia on cerebral blood flow in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1980 May. 121(5):813-8. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.